

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 April 2009 (09.04.2009)

PCT

(10) International Publication Number
WO 2009/043448 A3

(51) International Patent Classification:

A61K 38/22 (2006.01) A61P 31/00 (2006.01)
A61P 3/00 (2006.01) A61P 35/00 (2006.01)
A61P 9/00 (2006.01) A61P 37/00 (2006.01)
A61P 11/00 (2006.01) A61P 31/18 (2006.01)
A61P 25/28 (2006.01)

(21) International Application Number:

PCT/EP2008/007619

(22) International Filing Date:

9 September 2008 (09.09.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

07017755.5 11 September 2007 (11.09.2007) EP

(71) Applicant (for all designated States except US): **MONDO-BIOTECH LABORATORIES AG** [LI/LI]; Herrengasse 21, FL-9490 Vaduz (LI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BEVEC, Dorian** [DE/DE]; Kriegerstrasse 62, 82110 Germering (DE). **CAVALLI, Fabio** [CH/CH]; Via Pasquée 23, CH-6925 Gentilino (CH). **CAVALLI, Vera** [CH/CH]; Via Pasquée, 23, CH-6925 Gentilino (CH). **BACHER, Gerald** [DE/DE]; Masurenweg 5, 82110 Germering (DE).

(74) Agent: **ARTH, Hans-Lothar**; ABK Patent Attorneys, Jasminweg 9, D-14052 Berlin (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

18 June 2009

(54) Title: NEUROMEDIN U-25 AND NEUROMEDIN S AS THERAPEUTIC AGENTS

(57) Abstract: The present invention is directed to the use of the peptide compound Phe-Arg-Val-Asp- Glu-Glu-Phe-Gln-Ser-Pro-Phe-Ala-Ser-Gln-Ser-Arg-Gly-Tyr-Phe-Leu-Phe-Arg-Pro-Arg- Asn-NH₂ as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Phe-Arg-Val-Asp-Glu-Glu-Phe-Gln-Ser- Pro-Phe-Ala-Ser-Gln-Ser-Arg-Gly-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH₂ optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

WO 2009/043448 A3

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2008/007619

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K38/22 A61P3/00 A61P9/00 A61P11/00 A61P25/28 A61P31/00 A61P35/00 A61P37/00 A61P31/18		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61K A61P		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, EMBASE, WPI Data, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2007/022123 A (AMYLIN PHARMACEUTICALS INC [US]; LEVY ODILE ESTHER [US]; HANLEY MICHAEL) 22 February 2007 (2007-02-22) abstract paragraphs [0109], [0311], [0312]	1-15
X	WO 2006/086769 A (AMYLIN PHARMACEUTICALS INC [US]; LEVY ODILE ESTHER [US]; HANLEY MICHAEL) 17 August 2006 (2006-08-17) abstract paragraphs [0092], [0385], [0391], [0392]	1-15
X	WO 2007/075439 A (AMYLIN PHARMACEUTICALS INC [US]; YOUNG ANDREW A [US]; MCQUAID SARAH L) 5 July 2007 (2007-07-05) paragraphs [0002], [0037], [0236]	1-15
-/-		
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family		
Date of the actual completion of the international search	Date of mailing of the international search report	
28 April 2009	13/05/2009	
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Pilling, Stephen	

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/007619

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2006/293232 A1 (LEVY ODILE E [US] ET AL) 28 December 2006 (2006-12-28) abstract paragraphs [0078], [0093], [0101], [0270], [0271] -----	1-15
X	EP 1 829 969 A (JAPAN GOVERNMENT [JP]; TAKEDA PHARMACEUTICAL [JP]) 5 September 2007 (2007-09-05) paragraphs [0003], [0004], [0162], [0202], [0205], [0212] - [0215] -----	1-15
P,X	WO 2008/097536 A (AMYLIN PHARMACEUTICALS INC [US]; LAUGERO KEVIN D [US]; HANLEY MICHAEL) 14 August 2008 (2008-08-14) abstract paragraph [0045] -----	1-15
P,X	WO 2007/109135 A (MERCK & CO INC [US]; ANGELETTI P IST RICHERCHE BIO [IT]; MARSH DONALD) 27 September 2007 (2007-09-27) abstract table 1; sequence 2 page 20, line 2 - line 8 -----	1-15
P,X	DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 14 March 2008 (2008-03-14), KIMURA, NAOKI: "Cancer therapeutic agent comprising ligand for neuromedin U receptor 2 (FM4) molecule as active ingredient" XP002525454 retrieved from STN Database accession no. 2008:319385 abstract & WO 2008/029601 A1 (FORERUNNER PHARMA RESEARCH CO., LTD., JAPAN) 13 March 2008 (2008-03-13) -----	1-15
E	WO 2009/042053 A (MERCK & CO INC [US]; ANGELETTI P IST RICHERCHE BIO [IT]; MARSH DONALD) 2 April 2009 (2009-04-02) abstract page 3, line 13 - line 23 page 4, line 8 - line 16 page 13, line 19 - line 21 page 17, line 29 - line 34 ----- -/-	1-15

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/007619

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BRIGHTON P J ET AL: "Neuromedin U and Its Receptors: Structure, Function, and Physiological Roles" PHARMACOLOGICAL REVIEWS, WILLIAMS AND WILKINS INC., BALTIMORE, MD, US, vol. 56, no. 2, 1 January 2004 (2004-01-01), pages 231-248, XP003002000 ISSN: 0031-6997 the whole document	1-15
P,A	MORI KENJI ET AL: "Neuromedin S: Discovery and Functions" RESULTS AND PROBLEMS IN CELL DIFFERENTIATION SPRINGER-VERLAG BERLIN, HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SERIES : RESULTS AND PROBLEMS IN CELL DIFFERENTIATION (ISSN 0080-1844(PRINT)), 24 January 2008 (2008-01-24), pages 201-212, XP002524385 ISSN: 978-3-540-78350-3(H) the whole document	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2008/007619

Patent document cited in search report.		Publication date	Patent family member(s)	Publication date
WO 2007022123	A	22-02-2007	AU 2006279680 A1	22-02-2007
			CA 2617649 A1	22-02-2007
			EP 1922336 A2	21-05-2008
WO 2006086769	A	17-08-2006	AU 2006213607 A1	17-08-2006
			CA 2597649 A1	17-08-2006
			EP 1853627 A2	14-11-2007
			JP 2008530130 T	07-08-2008
			KR 20070115947 A	06-12-2007
			US 2009036364 A1	05-02-2009
WO 2007075439	A	05-07-2007	AU 2006329836 A1	05-07-2007
			CA 2634016 A1	05-07-2007
			EP 1973953 A2	01-10-2008
US 2006293232	A1	28-12-2006	US 2006094652 A1	04-05-2006
EP 1829969	A	05-09-2007	CA 2592201 A1	29-06-2006
			WO 2006068326 A1	29-06-2006
			US 2008124335 A1	29-05-2008
WO 2008097536	A	14-08-2008	NONE	
WO 2007109135	A	27-09-2007	AU 2007227510 A1	27-09-2007
			CA 2647027 A1	27-09-2007
			EP 1999143 A2	10-12-2008
			KR 20090005329 A	13-01-2009
			US 2007244048 A1	18-10-2007
WO 2008029601	A1	13-03-2008	CA 2656227 A1	13-03-2008
WO 2009042053	A	02-04-2009	NONE	